The survival of patients with metastatic prostate cancer improves by adding darolutamide to their treatment. That is the conclusion of a recent study. Internist-oncologist Tom van der Hulle has a number of comments on this study.
Patients with hormone-sensitive metastatic prostate cancer are treated with androgen deprivation therapy (ADT), ie an orchiectomy or treatment with a gonadorelin agonist or antagonist. Their survival improves when they additionally receive docetaxel, abiraterone or a second generation androgen receptor antagonist (ARA). Darolutamide is a new ARA that crosses the blood-brain barrier less and possibly less…
The entire contents of this article are only accessible to subscribers.
Read 3 articles FREE
Make an account. Free and without obligation.
I want 3x free
Always access to all NTvG publications?
Subscribe today!
Take the introductory subscription
€ 31.95 for 12 weeks!
I want to meet
Do you already have a subscription? login